EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：79
|
作者：
Ke, E-E [1 ,2 ]
Wu, Yi-Long [1 ,2 ]
机构：
[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期
关键词：
GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;
D O I：
10.1016/j.tips.2016.09.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.
引用
收藏
页码：887 / 903
页数：17
相关论文
共 50 条
  • [1] Treatment choice in EGFR-mutant non-small-cell lung cancer
    Brueckl, Wolfgang M.
    LANCET ONCOLOGY, 2017, 18 (11): : 1425 - 1426
  • [2] Spontaneously expectorated EGFR-mutant non-small-cell lung cancer
    Sumi, Toshiyuki
    Terai, Kotomi
    Chiba, Hirofumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (11) : 1094 - 1095
  • [3] The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Fei Zhou
    Haoyue Guo
    Yang Xia
    Xiuning Le
    Daniel S. W. Tan
    Suresh S. Ramalingam
    Caicun Zhou
    Nature Reviews Clinical Oncology, 2025, 22 (2) : 95 - 116
  • [4] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [5] Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET RESPIRATORY MEDICINE, 2017, 5 (09): : 669 - 671
  • [6] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
    Wu, Fang
    Liu, Xianling
    Ma, Jin-an
    Gao, Yawen
    Hu, Chunhong
    LANCET ONCOLOGY, 2018, 19 (03): : E124 - E124
  • [7] Targeting MET amplification in EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Chaib, Imane
    Santarpia, Mariacarmela
    LANCET RESPIRATORY MEDICINE, 2020, 8 (11): : 1068 - 1070
  • [8] Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Bain, Nathan T. T.
    Wang, Yang
    Arulananda, Surein
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [10] Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
    Fan, Y.
    Yu, X.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2228
12345